1.47

1.40% -0.02

Regulus Therapeutics Inc (RGLS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Regulus Therapeutics Inc stock is traded at $1.47, with a volume of 225.95K. It is down -1.40% in the last 24 hours and down -7.01% over the past month. Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Previous Close:

$1.49

Open:

$1.5

24h Volume:

225.95K

Relative Volume:

0.68

Market Cap:

$96.23M

Revenue:

Net Income/Loss:

$-30.04M

P/E Ratio:

-0.8698

EPS:

-1.69

Net Cash Flow:

$-27.38M

1W Performance:

-8.75%

1M Performance:

-7.01%

6M Performance:

-44.56%

1Y Performance:

+5.70%

1-Day Range:

$1.46

$1.515

1-Week Range:

$1.46

$1.68

52-Week Range:

$1.08

$3.79

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name

Regulus Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

858-202-6300

Address

4224 CAMPUS POINT COURT, SAN DIEGO, CA

Employee

Twitter

@regulusrx

Next Earnings Date

2024-11-07

Latest SEC Filings

RGLS's Discussions on Twitter

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-02-24	Initiated	Oppenheimer	Outperform
Mar-18-24	Initiated	Leerink Partners	Outperform
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral
Jan-05-18	Initiated	Leerink Partners	Outperform
Jun-13-17	Reiterated	Chardan Capital Markets	Buy
Mar-06-17	Reiterated	Wedbush	Outperform
Jan-30-17	Downgrade	Needham	Buy → Hold
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Dec-07-16	Reiterated	Chardan Capital Markets	Buy
Nov-02-16	Reiterated	Needham	Buy
Jul-25-16	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	FBR Capital	Outperform
Jun-28-16	Reiterated	Needham	Buy
Jun-07-16	Reiterated	Chardan Capital Markets	Buy
Apr-13-16	Initiated	Chardan Capital Markets	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform
Nov-24-14	Initiated	Deutsche Bank	Buy
Aug-07-14	Reiterated	FBR Capital	Outperform
Aug-14-13	Reiterated	Needham	Buy

View All

Regulus Therapeutics Inc Stock (RGLS) Latest News

Oct 30, 2024

HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Oct 30, 2024

Oct 29, 2024

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat

Oct 29, 2024

Oct 24, 2024

Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India

Oct 24, 2024

Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa

Oct 24, 2024

Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com

Oct 24, 2024

Oct 19, 2024

Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World

Oct 19, 2024

Oct 13, 2024

Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Oct 13, 2024

Oct 08, 2024

HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat

Oct 08, 2024

RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 08, 2024

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire

Oct 08, 2024

Oct 04, 2024

Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat

Oct 04, 2024

Oct 03, 2024

Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Oct 03, 2024